Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
BioSpace
BioSpace
Human Factors Minute
Human Factors Cast
Two Inconvenient Women
ThoughtBox Education
Today's Creation Moment
Creation Moments
The Spark Bird Podcast
Jenn Lodi-Smith and Janet McNally
The Village Jedi
The Village Jedi
The BioHub - by Avetix
Max Brennan - Biotech HeadHunter
Space News and Weather Today – Auroras, Rocket Launches & Night Sky Viewing
Caloroga Labs Space News and Weather
אבולוציה זו לא מילה גסה
יהודה סמואל
跨国串门儿计划
yikai
New Books in Political Science
New Books Network
New Books in Communications
Marshall Poe
New Books in Law
New Books Network
New Books in Science, Technology, and Society
New Books Network
Småbrukarpodden
Tess och Mattias
New Books in Language and Translation
Marshall Poe
Molecule to Market: Inside the outsourcing space
Raman Sehgal
The Archaeology Podcast Network Feed
The Archaeology Podcast Network
New Books in Urban Studies
New Books Network
Galactic Horrors
Galactic Horrors
THE BIG BUCK THEORY
Izaak Young
The BoldlyGo Podcast: Revolutionizing Your Journey
DeAndre Coke
West Palm Beach Weather Daily
Fast Foundations
Montreal Weather Daily
Fast Foundations
Toronto Weather Daily
Fast Foundations
Philadelphia Weather Daily
Fast Foundations
Big Crystal Energy Podcast - Crystals, Glamour, and Magic for Liminal Spaces
Ashleigh Bodell
Le temps d'une rencontre
Cairn.info
Planetterrian Daily
Patrick
Physio Edge podcast with David Pope
David Pope
Wissenschaft
Holger Klein, Florian Freistetter
Untold Radio Network
Untold Radio Network
The Human Upgrade: Biohacking for Longevity & Performance
Dave Asprey
Understand All
Aaron Barlow
TED-Ed
TED-Ed
The Humble Hoof
Alicia Harlov
Sur les traces de la Préhistoire
ICI Périgord
Science
BioSpace
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted in...
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for deriske...
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivo...
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We ex...
This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and this week, AbbVie notched another one for the second quarter, sc...
In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serve...
Moderna’s mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisor...
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life sc...
Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide—not just for weight loss but also for other ind...
In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hai...
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show. For RevMed...
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, m...
Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine development with three separate buys in the space. Outside of vaccines,...
In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Ande...
FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units also left their posts, as did the FDA chief of staff and chie...
In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT ...
Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that President Donald Trump had signed off on his ouster. The president in...
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpackin...
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the Ne...
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the Ne...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.